(19)
(11) EP 3 118 223 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
15.04.2020 Bulletin 2020/16

(45) Mention of the grant of the patent:
19.02.2020 Bulletin 2020/08

(21) Application number: 16183733.1

(22) Date of filing: 30.12.2008
(51) International Patent Classification (IPC): 
C07K 16/24(2006.01)
C12N 15/13(2006.01)
A61P 1/00(2006.01)
 A61K 39/395(2006.01)
A61P 35/00(2006.01)
A61P 13/12(2006.01)

(54)

ANTI MIF ANTIBODIES FOR USE IN TREATING INFLAMMATORY DISEASES

ANTI-MIF-ANTIKÖRPER ZUR BEHANDLUNG VON ENTZÜNDUNGSKRANKHEITEN

ANTICORPS ANTI MIF POUR UTILISATION DANS LE TRAITEMENT DE MALADIES INFLAMMATOIRES

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
Designated Extension States:
AL BA MK RS

(30) Priority: 04.01.2008 US 18988 P
05.09.2008 US 94685 P

(43) Date of publication of application:
18.01.2017 Bulletin 2017/03

(62) Application number of the earlier application in accordance with Art. 76 EPC:
14163839.5 / 2754671
12189220.2 / 2548890
08869976.4 / 2231707

(73) Proprietors:
  • Baxalta Incorporated
    Bannockburn, IL 60015 (US)
  • Baxalta GmbH
    8152 Glattpark, Opfikon (CH)
  • Dyax Corporation
    Cambridge, MA 02139 (US)

(72) Inventors:
  • Kerschbaumer, Randolf
    3400 Klosterneuburg (AT)
  • Scheiflinger, Friedrich
    1090 Vienna (AT)
  • Rieger, Manfred
    2100 Korneuburg (AT)
  • Thiele, Michael
    1030 Vienna (AT)
  • Mudde, C. Geert
    2384 Breitenfurt (AT)
  • Muellberg, Jürgen
    Lexington, MA 02420 (US)
  • Hoet, Rene
    3705 TB Zeist (NL)

(74) Representative: Hoffmann Eitle 
Patent- und Rechtsanwälte PartmbB Arabellastraße 30
81925 München
81925 München (DE)


(56) References cited: : 
WO-A-98/17314
US-A- 6 030 615
US-A1- 2003 235 584
 WO-A-2007/134538
US-A1- 2003 099 653
US-A1- 2004 156 848
   
  • KAWAGUCHI T ET AL: "A monoclonal antibody against migration inhibitory factor (MIF) obtained by immunization with MIF from the human lymphoblast cell line Mo.", JOURNAL OF LEUKOCYTE BIOLOGY FEB 1986, vol. 39, no. 2, February 1986 (1986-02), pages 223-232, XP002524748, ISSN: 0741-5400
  • WEISER W Y ET AL: "Generation of human hybridomas producing migration inhibitory factor (MIF) and of murine hybridomas secreting monoclonal antibodies to human MIF", CELLULAR IMMUNOLOGY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 90, no. 1, 1 January 1985 (1985-01-01), pages 167-178, XP024004738, ISSN: 0008-8749 [retrieved on 1985-01-01]
  • OGAWA HIDEAKI ET AL: "An Antibody for Macrophage Migration Inhibitory Factor Suppresses Tumour Growth and Inhibits Tumour-Associated Angiogenesis", CYTOKINE, ACADEMIC PRESS LTD, PHILADELPHIA, PA, US, vol. 12, no. 4, 1 April 2000 (2000-04-01), pages 309-314, XP008090736, ISSN: 1043-4666
  • RUPREHT R R ET AL: "Murine monoclonal antibodies directed against human recombinant Macrophage Migration Inhibitory Factor", PFLUEGERS ARCHIV: EUROPEAN JOURNAL OF PHYSIOLOGY, SPRINGER VERLAG, BERLIN, DE, vol. 440, no. 5, suppl, 1 January 2000 (2000-01-01), pages R78-R80, XP008090980, ISSN: 0031-6768
  • LEUNG JOSEPH C K ET AL: "Anti-macrophage migration inhibitory factor reduces transforming growth factor-beta 1 expression in experimental IgA nephropathy.", NEPHROLOGY, DIALYSIS, TRANSPLANTATION : OFFICIAL PUBLICATION OF THE EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION - EUROPEAN RENAL ASSOCIATION AUG 2004, vol. 19, no. 8, August 2004 (2004-08), pages 1976-1985, XP002524749, ISSN: 0931-0509
  • WILLIS MONTE S ET AL: "Macrophage migration inhibitory factor mediates late cardiac dysfunction after burn injury", AMERICAN JOURNAL OF PHYSIOLOGY: HEART AND CIRCULATORY PHYSIOLOGY, THE AMERICAN PHYSIOLOGICAL SOCIETY, vol. 288, no. 2, 1 February 2005 (2005-02-01), pages H795-H804, XP009104102, ISSN: 0363-6135
  • YANG ZHANG ET AL: "Characterization, epitope identification and mechanisms of the anti-septic capacity of monoclonal antibodies against macrophage migration inhibitory factor", INTERNATIONAL IMMUNOPHARMACOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 11, no. 9, 25 April 2011 (2011-04-25) , pages 1333-1340, XP028265421, ISSN: 1567-5769, DOI: 10.1016/J.INTIMP.2011.04.017 [retrieved on 2011-05-03]
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).